Med-tech MNCs see healthy market space

A1 In the past five years, the CIIE has become a very important stage for the debut of global innovative products and cutting-edge technologies, and it has also built an excellent platform for communications and exchanges between the government and enterprises, and between enterprises.

The 20th National Congress of the Communist Party of China just closed. We believe the opening of the fifth CIIE at this point fully demonstrates the country's commitment to achieving high-quality economic development and its new strides in reform and opening-up.

We believe that the convening of the CIIE will provide more "Chinese opportunities" for the rest of the world. Roche is encouraged, with stronger confidence in and commitment to the Chinese market.

A2 It's a great honor for Roche to attend the CIIE for five consecutive years. With one of the largest booth areas in the medical and healthcare pavilion, Roche highlights a full portfolio of launched and market-ready products at its 1,000-square-meter booth, including nearly 10 global innovative products that will soon be launched in China, covering major disease areas such as hematological tumors, breast cancer, ophthalmology and neuroscience.

At the expo, Roche holistically showcases multiple innovative projects and solutions. We hope to leverage the CIIE as a bridge to align with the Chinese government and partners in enhancing exchange and collaboration, seeking synergies in resources to foster industry development, and jointly building, creating and sharing the healthcare ecosystem in China.

A3 In recent years, we have seen that China has further deepened reform, which has unleashed more market vitality and economic resilience. Recently, a series of policies have been introduced to help increase, stabilize and improve the quality of foreign investment. We firmly believe that these positive measures will further boost our confidence in continuing to deepen our business in China, increase our business in China and invest in China.

A4 China has become the world's second-largest pharmaceutical market. Global companies like Roche have benefited from the country's opening-up and economic reform, which has led to a favorable business environment and easier market access.

In the healthcare sector, we have seen significant improvements in policies and measures to accelerate the regulatory approval and affordability of innovative drugs in recent years, to promote the transformation and upgrading of the industry and the high-quality development of the economy and society. We are also heartened to see that the government places a strategic priority on ensuring people's health and improving policies for promoting public health, which shows the government's commitment to elevating the health and well-being of the Chinese people.